AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 4, 2026, 4:01 PM ET BioCryst plans to present at the 2026 Jefferies Global Healthcare Conference on November 18, 2026, and the 9th Annual Evercore Healthcare Conference on December 1, 2026. AI-generated summary · Source: company release
Nasdaq: $BCRXORLADEYO franchiseNavenibart developmentDebt and execution risk

BCRX Stock Hub: BioCryst News, ORLADEYO and Navenibart

Q3 ORLADEYO revenue reached $174.833 million and GAAP net income was $37.916 million; the completed November 6 close was $7.69, +0.79% on the day. September cash and investments were $374.998 million, plus $1.451 million restricted cash. BioCryst increased total-revenue guidance, kept ORLADEYO guidance unchanged and reduced its non-GAAP expense range. Initial CareMed inventory sits in the comparison without a quantified contribution, while ACAAI posters precede initial BCX17725 patient data expected by year-end and ALPHA-ORBIT topline expected Q3 2027. November 4 results.

Last updated: November 6, 2026Market reference: November 6, 2026 completed U.S. regular-session close $7.69 ($7.63 on November 5; +0.79%)Financial period: quarter and nine months ended September 30, 2026; U.S. GAAPCurrency: USD
Full research report · PDF
BioCryst research updated November 6, 2026
Q3 results, the November 6 market reference, 10-Q cash flows and debt, share counts, CareMed inventory, ORLADEYO and HAE pipeline milestones. Personal use only: redistribution prohibited.
Get the report (PDF)
Next scheduled scientific event
November 12-16, 2026 – ACAAI

Four posters cover ORLADEYO outcomes and pediatric dosing, plus interim ALPHA-SOLAR navenibart follow-up. The announcement provides presentation topics and times. These differ from ALPHA-ORBIT pivotal results, expected Q3 2027. Company development windows. Source.

BCX17725 initial Part 4 Netherton patient data are expected by year-end 2026. The company is also scheduled to present at the Jefferies Global Healthcare Conference in London on November 18 at 8:30 a.m. ET and at the Evercore Healthcare Conference on December 1 at 8:45 a.m. ET. Conference announcement. Company guidance windows differ from completed results.
BioCryst Pharmaceuticals BCRX daily stock chart
Daily chart $BCRX. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

BCRX stock at a glance

Close · November 6, 2026
$7.69
Completed regular session; +0.79% from the November 5 close of $7.63.
Price series in PDF, page 2
Q3 total revenue
$180.292M
ORLADEYO $174.833M; license and other $5.459M
Source
Q3 GAAP net income
$37.916M
Basic EPS $0.15; diluted $0.14
Source
Cash and investments
$374.998M
September 30; restricted cash $1.451M separate
Source
Secured term loan
$395.609M
September 30 carrying balance; contractual principal $400M, due January 23, 2031
Source Q3 10-Q
Royalty financing balance
$421.683M
September 30 selected company balance-sheet disclosure
Source
Common shares – September 30
256.118M
Rounded company disclosure; October 30 cover 257,299,269
Source Q3 10-Q
Q3 GAAP / non-GAAP operating profit
$53.330M / $86.547M
Company adjustment $33.217M; distinct from net income
Source

Where BioCryst stands now

Q3 total revenue was $180.292 million, including ORLADEYO $174.833 million and license/other revenue $5.459 million. GAAP operating profit was $53.330 million and net income $37.916 million; basic EPS was $0.15 and diluted EPS $0.14. Company-defined non-GAAP operating profit was $86.547 million and net income $71.133 million after $33.217 million specified exclusions. Source.

CareMed built initial inventory during the specialty-pharmacy transition. BioCryst did not quantify its contribution and expects the inventory level to remain relatively stable. Total revenue grew 13% reported and 24% excluding Europe. The 24% comparison concerns total revenue; the company gives no separate inventory-adjusted ORLADEYO growth percentage. Source.

Full-year total-revenue guidance increased to $715-730 million from $690-715 million, ORLADEYO remained $625-645 million, and non-GAAP operating-expense guidance declined to $415-425 million from $420-440 million. Licensing, international RAPIVAB orders and expense exclusions affect interpretation. Source.

The constructive case

The marketed ORLADEYO franchise, new formulation access and operating profitability support a more focused rare-disease development strategy. Continued patient demand and controlled costs could help fund navenibart and BCX17725. Clinical milestones offer opportunities to test the development case.

The cautious case

Initial channel inventory differs from patient demand. Acquisition-related accounting, royalties, debt and restructuring complicate financial comparisons. Competition and reimbursement can affect ORLADEYO uptake, while pivotal navenibart efficacy and BCX17725 outcomes remain unresolved.

Latest BioCryst Pharmaceuticals news

Nov 4, 2026

BioCryst to Present at Upcoming Investor Conferences

BioCryst plans to present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026. It also plans to present at the 9th Annual Evercore Healthcare Conference in Coral Gables, FL, on Tuesday, December 1, 2026. Live audio webcasts and replays will be available in the Investors & Media section of BioCryst's website at www.biocryst.com.

Nov 4, 2026

BioCryst Reports Third Quarter 2026 Financial Results

BioCryst reported total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million for the quarter ended September 30, 2026. Operating profit was $53.3 million and Non-GAAP operating profit was $86.5 million. The company maintained its full year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million.

Oct 29, 2026

Four ACAAI posters scheduled for November

The November 13–15 posters address ORLADEYO real-world utilization, pediatric dose adjustment and interim ALPHA-SOLAR navenibart findings. This announcement gives a presentation schedule rather than results.

Oct 21, 2026

Q3 results scheduled for November 4

The company schedules results November 4 with a conference call and webcast at 8:30 a.m. Eastern.

Oct 21, 2026

ORLADEYO 150 mg pellets approved for adults and adolescents

The company announced approval of the pellet formulation for prophylaxis in HAE patients aged 12 and older. Formulation approval is distinct from navenibart development or a quantified sales impact.

Oct 5, 2026

Scientific advisory board formed

The new board supports pipeline and development strategy. Formation is an organizational step rather than new clinical data or revised financial guidance.

BCRX stock catalysts: ACAAI, BCX17725 and ALPHA-ORBIT

  • November 4, 2026 – Q3 results and updated guidance. Reported
  • November 12-16, 2026 – Four ACAAI posters; ALPHA-SOLAR interim poster November 15. Scheduled
  • November 18, 2026, 8:30 a.m. ET – Presentation at the Jefferies Global Healthcare Conference, London; webcast on the company website. Investor event
  • December 1, 2026, 8:45 a.m. ET – Presentation at the 9th Annual Evercore Healthcare Conference, Coral Gables, Florida; webcast on the company website. Investor event
  • By year-end 2026 – Initial BCX17725 Part 4 Netherton patient data, cohort enrolled. Company window
  • By year-end 2026 – Birmingham closure substantially complete. Company expectation
  • Q3 2027 – Fully enrolled ALPHA-ORBIT six- and twelve-month endpoint topline. Company expectation

ACAAI is a scientific meeting, while the later pivotal topline has a separate evidentiary role. Investor conference schedule. Poster schedule. Source.

Navenibart: pivotal enrollment and longer-term follow-up

ALPHA-ORBIT is fully enrolled, and the company expects six- and twelve-month endpoint topline in Q3 2027. The ALPHA-SOLAR interim ACAAI poster and ORBIT-EXPANSE longer-term follow-up are separate studies. Less-frequent injectable prophylaxis remains investigational and faces efficacy, safety and competitive questions. Source.

The ALPHA-ORBIT registry lists 157 actual participants and a primary time-normalized investigator-confirmed HAE attack measure through Day 181. Registry estimated completion dates and the company’s Q3 2027 topline window describe different milestones. Source.

BCRX earnings: profit, cash context and financial obligations

Nine-month revenue was $554.955 million, operating loss $549.803 million and net loss $605.501 million, including $697.761 million acquired in-process R&D from Astria. Company-defined non-GAAP net income was $198.246 million after $803.747 million specified exclusions. Accounting adjustments differ from transaction economics and cash funding. Source.

September cash and investments were $374.998 million, with $1.451 million restricted cash separate. Secured-loan carrying balance was $395.609 million, royalty financing $421.683 million and shareholders’ deficit $397.384 million. The Q3 Form 10-Q filed November 4 reports $75.534 million of operating cash inflow over the first nine months, against $42.551 million in H1, and $0.845 million of capex. It states that resources available at September 30 are expected to fund operations for at least the next 12 months. Q3 Form 10-Q. Source.

The company reports a rounded 256.118 million common shares at September 30; the Q3 Form 10-Q cover reports 257,299,269 on October 30 (255,535,105 on July 31). Astria consideration included 37.282 million newly issued shares earlier in the year and $489.480 million cash paid net of acquired cash. Actual shares, weighted EPS denominators and acquisition accounting have distinct roles. H1 acquisition and cover details. Source.

The November 4 Form 10-Q reports $75.534 million of operating cash inflow, $457.671 million of investing outflow, $389.323 million of financing inflow and $0.845 million of capital expenditures over nine months. The corresponding H1 figures were $42.551 million inflow, $378.796 million outflow, $401.399 million inflow and $0.612 million of capital expenditures. Subtracting H1 gives Q3 operating cash inflow of $32.983 million, investing outflow of $78.875 million, financing outflow of $12.076 million and $0.233 million of capital expenditures. With a positive $0.006 million currency effect, Q3 cash, equivalents and restricted cash decreased $57.962 million. September Form 10-Q. June Form 10-Q.

At September 30 the Blackstone secured term loan had $400 million principal and $395.609 million carrying value. It matures January 23, 2031 and requires quarterly interest-only payments until maturity. The contractual base rate is three-month SOFR, floored at 1.75%, plus 4.50%. Before January 23, 2028 and with no ongoing default, BioCryst may capitalize up to 200 basis points of interest accrued in a quarter. The additional annual margin of 0.50 percentage points applies to the capitalized portion. The company reported $43.745 million current and $377.938 million noncurrent royalty financing obligations. Total liabilities were $988.454 million. Management expects available resources to fund operations for at least 12 months. September Form 10-Q.

Merlintrader Health Score · $BCRX

3.15out of 5
Balance sheet and runway · 30%3.0

September 30, 2026 cash and investments were $374.998 million, with $1.451 million restricted cash separate. Q3 net income and the $32.983 million Q3 operating cash inflow derived from the June and September filings support financial flexibility. Secured-loan carrying value of $395.609 million, royalty financing of $421.683 million and a $397.384 million shareholders’ deficit constrain the assessment; no cash-exhaustion date is implied.

Catalyst · 30%3.0

The next scheduled scientific event is ACAAI November 12-16, 2026. BCX17725 initial Part 4 Netherton data are expected by year-end 2026, with the cohort enrolled. Fully enrolled ALPHA-ORBIT six- and twelve-month endpoint topline is expected Q3 2027. Poster topics, early clinical findings and pivotal results have distinct evidentiary roles.

Dilution · 20%3.5

The company reports a rounded 256.118 million common shares at September 30, 2026, versus 255.265 million at June 30. The October 30 Form 10-Q cover lists 257,299,269 shares. The Astria transaction issued 37.282 million shares earlier in the year. Employee awards and future financing can affect ownership; the quarterly basic and diluted weighted EPS denominators differ from actual end-period shares.

Liquidity · 10%3.0

The completed November 6, 2026 close was $7.69, and the November 4 post-release session closed at $8.24 with 4,519,600 shares traded. Twenty completed sessions averaged 3,359,150 shares. Observed turnover supports tradability, while earnings, clinical news and financing can cause gaps and uneven execution. Dated short-interest percentages are separate from current market depth.

Execution · 10%3.5

Q3 2026 operating profit was $53.330 million and ORLADEYO revenue $174.833 million. Pediatric access, the October 150 mg pellet approval and expense discipline support execution. Initial CareMed inventory affects the sales comparison, while Birmingham savings, pivotal navenibart results and BCX17725 outcomes remain future tests.

Reassessed November 6, 2026. Weighted calculation: 3.0 × 30% + 3.0 × 30% + 3.5 × 20% + 3.0 × 10% + 3.5 × 10% = 3.15 / 5. Financial and operational robustness over twelve to eighteen months; not an investment recommendation or a price target.

Red flags

  • Initial CareMed inventory affects shipments and differs from patient demand.
  • The release does not quantify the channel inventory contribution.
  • Total-revenue guidance includes licensing and RAPIVAB orders as well as ORLADEYO.
  • Non-GAAP profitability excludes acquisition, compensation and restructuring costs.
  • The nine-month GAAP loss includes $697.761 million acquired in-process R&D.
  • Debt, royalty obligations and negative book equity constrain financial flexibility.
  • The $400 million term loan principal is due in full at the January 23, 2031 maturity.
  • HAE prophylaxis has established oral and injectable competitors.
  • Navenibart pivotal efficacy, safety and real-world differentiation remain unresolved.
  • BCX17725 early patient data cannot establish late-stage clinical benefit.
  • Birmingham cash costs and projected annual savings have different timing.
  • STAR-0310 development has been discontinued.
  • Employee awards and future equity financing can dilute ownership.

BCRX Stock FAQ: BioCryst Questions Answered

When is the next BCRX stock catalyst?

As of November 4, 2026, BioCryst’s next scheduled scientific event is ACAAI November 12-16. Four posters cover ORLADEYO outcomes and interim ALPHA-SOLAR navenibart follow-up. Initial BCX17725 Part 4 patient data are expected by year-end 2026. ALPHA-ORBIT pivotal six- and twelve-month endpoint topline remains expected Q3 2027. The poster schedule and company clinical windows have different status. Source. ACAAI presentation schedule.

Which BioCryst ORLADEYO formulations are FDA approved?

On October 21, 2026, BioCryst announced FDA approval of 150 mg ORLADEYO oral pellets for prophylaxis in patients twelve and older, alongside capsules for that age group. Pediatric pellets had already been approved in December 2025 for ages two to under twelve. ORLADEYO prevents HAE attacks; it is not an acute-attack treatment. Formulation choice, administration and safety requirements follow the applicable label. Source.

How much cash does BioCryst have and is it profitable?

At September 30, 2026, BioCryst reported $374.998 million cash and investments, plus $1.451 million restricted cash. Q3 GAAP net income was $37.916 million, and the Q3 Form 10-Q reports $75.534 million of operating cash inflow over the first nine months. Its secured-loan carrying balance was $395.609 million and reported royalty financing $421.683 million. Funding depends on commercial collections, costs and contractual payments rather than a published cash-exhaustion date. Source. Q3 Form 10-Q.

Is BCRX stock exposed to share dilution?

At September 30, 2026, BioCryst reported a rounded 256.118 million common shares in its quarterly release. The Q3 Form 10-Q cover reports 257,299,269 shares on October 30 (255,535,105 on July 31). Astria consideration included 37.282 million newly issued shares earlier in the year. Employee awards and future financing remain potential dilution sources. Quarterly basic/diluted weighted EPS shares of 255.634/267.621 million are different from actual shares outstanding. Source. Q3 10-Q cover. H1 acquisition shares.

When does BioCryst report earnings next?

As of November 4, 2026, BioCryst has not announced its next earnings date. It released Q3 results November 4 with an 8:30 a.m. Eastern earnings call. Total revenue was $180.292 million, ORLADEYO revenue $174.833 million and GAAP net income $37.916 million. Full-year guidance and upcoming scientific posters are separate from an announced future earnings release. Source.

What does BioCryst Pharmaceuticals do?

In its November 4, 2026 update, BioCryst describes a rare-disease business centered on HAE. ORLADEYO is marketed oral prophylaxis, while acquired navenibart is an investigational long-acting injectable plasma-kallikrein inhibitor. BCX17725 targets KLK5 in Netherton syndrome. The company is focusing on external innovation and has discontinued the separate early-stage STAR-0310 atopic-dermatitis program. Commercial products and investigational candidates have different development and financial risks. Source.

Did channel inventory affect BioCryst’s Q3 ORLADEYO sales?

In its November 4, 2026 release, BioCryst said CareMed built initial ORLADEYO inventory during the specialty-pharmacy transition, benefiting Q3 revenue. It did not quantify the contribution and expects the inventory level to remain relatively stable. The company says ORLADEYO excluding Europe grew without that stock build, but provides no separate inventory-adjusted growth percentage. Distributor shipments and patient demand are different measures. Source.

Why does BioCryst report a nine-month loss alongside Q3 profit?

For the nine months ended September 30, 2026, BioCryst reported a $605.501 million GAAP net loss including $697.761 million acquired in-process R&D from Astria. Q3 alone earned $37.916 million under GAAP. Company-defined non-GAAP net income was $198.246 million over nine months after specified exclusions. Acquisition accounting, actual purchase cash, stock compensation and recurring commercial earnings measure different aspects of the business. Source.

Primary sources

Market reference: completed November 6, 2026 U.S. regular-session close $7.69, after the November 5 close of $7.63. Interactive Brokers price and volume history underlies the report chart.

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $BCRX or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and commercial companies can still require financing. BioCryst faces risks from product demand, reimbursement, debt service, continuing royalty economics and investigational programs; a clinical result does not automatically determine the value of every approved asset. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.